Existing investors Gradient Ventures and Bloomberg Beta returned for a round that took the machine learning software developer's total funding to $27m.

The carmaker has followed up a $100m investment two years ago with a pledge to provide up to $200m for the Stanford-originated solid-state battery developer.

The protein degradation-focused drug developer, a spinout from Dana-Farber Cancer Institute, received $150m in series B funding and $20m in venture debt.

Wandelbots, which came out of Technical University of Dresden research, secured the funding as it publicly launched its robotics training software tool.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

4D Molecular Therapeutics secured the return of Berkeley Catalyst Fund for a series C round that follows plans for a $100m IPO announced in September 2019.

Pfizer Ventures and Chiesi Ventures returned to back inherited disease therapy developer 4D Molecular Therapeutics, which filed to go public in September.

The carmaker has followed up a $100m investment two years ago with a pledge to provide up to $200m for the solid-state battery developer.

The Roche, Novartis and Kraft Group-backed, protein degradation-focused drug developer received $150m in series B funding and $20m in venture debt.

SK China, Xiaomi and Lenovo were among the investors as BYD's electric vehicle chip spinoff added $113m to the $265m it announced last month.